TICKERNERD
Menu
SRZNSRZNHealthcare · Biotechnology

SRZN Stock Forecast: Surrozen, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$28
+11.23% on the day

The 6 Wall Street analysts covering Surrozen, Inc. hold a median 12-month price target of $52 — +85.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 77 of 100 as at 8 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$309.9M
Ticker Nerd rank
77 / 100
Median analyst target
$52
Analysts covering
6
Revenue$5.0M+408.6% y/y
Operating income−$10.4M
Net income$50.2M
Free cash flow−$7.4M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−6.8%
1M
+35.3%
YTD
+23.8%
1Y
+99.2%
From 52W high
−18.0%
From 52W low
+137.0%
$12
$34
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

SRZN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Surrozen, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
77 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
94
Momentum
90
Revisions
86
Size
60
Value
57
Volatility
45
Issuance
41
Quality
34
Growth
30

Accruals (94): Reported profit is backed by cash, and the company is not expanding recklessly.

Growth (30): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

SRZN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SRZN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$20$30$40$50$60Jan 26Apr 26Jul 26Oct 26SRZNHigh $54Median $52Low $40

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says6 analysts
6 Buy0 Hold0 Sell
Low $40Median $52High $54

The green dot is the last close — the median target sits +85.9% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 2 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
25 Sept 2026HC Wainwright & Co.MaintainsBuy$44 → $54
20 Aug 2026William BlairInitiatesOutperform—
20 Aug 2026William BlairInitiatesOutperform—
10 Aug 2026HC Wainwright & Co.ReiteratesBuy$44
10 Aug 2026HC Wainwright & Co.ReiteratesBuy—
7 May 2026HC Wainwright & Co.MaintainsBuy$36 → $44
7 May 2026HC Wainwright & Co.MaintainsBuy—
21 Apr 2026TD CowenInitiatesBuy—
24 Mar 2026Cantor FitzgeraldReiteratesOverweight—
24 Mar 2026HC Wainwright & Co.ReiteratesBuy—
19 Feb 2026Cantor FitzgeraldInitiatesOverweight—
12 May 2025HC Wainwright & Co.ReiteratesBuy—
2 Apr 2025HC Wainwright & Co.ReiteratesBuy—
30 Jan 2025HC Wainwright & Co.InitiatesBuy—
3 Jan 2025GuggenheimUpgradeBuy—
29 Nov 2022JP MorganDowngradeUnderweight—
18 Nov 2022GuggenheimDowngradeNeutral—
17 Nov 2022B of A SecuritiesDowngradeUnderperform$5.00 → $1.00
17 Oct 2022JP MorganInitiatesNeutral—
27 May 2022B of A SecuritiesDowngradeNeutral$5.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SRZN appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

SRZN vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, Surrozen, Inc. returned +99.2% against +16.2% for the S&P 500, dividends included.

SRZN vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250Jan 26Apr 26Jul 26Oct 26SRZNS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

SRZN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Surrozen, Inc. (SRZN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.8×

Cheaper than 82% of US stocks

Price / sales
26.9×

Cheaper than 8% of US stocks

Price / book
−1.4×

Cheaper than 95% of US stocks

EV / EBITDA
−4.9×

Cheaper than 79% of US stocks

Growth & margins
Revenue growth (YoY)
408.6%

Higher than 98% of US stocks

Earnings growth (YoY)
26.2%

Higher than 63% of US stocks

Gross margin
—
Operating margin
−207.4%

Higher than 11% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
128.9%

Higher than 97% of US stocks

Return on assets
−25.4%

Higher than 16% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Surrozen, Inc. (SRZN) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Surrozen, Inc. has a market value of $309.9M and an enterprise value of $214.2M.

  • Revenue in the twelve months to 30 June 2026: $11.5M. The latest quarter grew 408.6% year on year.

  • Net income over the same four quarters: −$332.1M, a −2885.3% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$35.0M.

  • Shares outstanding: 11.8M.

  • Trailing P/E: −0.8×; forward P/E: −6.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Surrozen, Inc. employs 44 people — $262K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 7 Oct 2026

Data provided by Twelve Data

Peers

SRZN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
SRZNSurrozen, Inc.$309.9M
77
CABACabaletta Bio, Inc.$317.9M
26
ARTVArtiva Biotherapeutics, Inc.$330.4M
33
OCGNOcugen, Inc.$330.9M
21
RLMDRelmada Therapeutics, Inc.$332.5M
64
PRLDPrelude Therapeutics, Inc.$309.0M
93
OBIOOrchestra Biomed Holdings, Inc.$335.3M
43

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Surrozen, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SRZN news & analysis

Surrozen Announces FDA Clearance of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema

GlobeNewsWire · 2 Oct 2026positive

Surrozen announced that its Investigational New Drug application for SZN-8141, a candidate for diabetic macular edema, has become effective, allowing the program to move into clinical development. The first patient in the DUET study is expected to be dosed in the fourth quarter of 2026, and this milestone triggers the second closing of a March 2025 private placement expected to provide approximately $95.1 million in gross proceeds.

Why it matters — The effective IND clears SZN-8141 to enter clinical development for a sight-threatening ophthalmic condition and unlocks substantial additional funding for Surrozen's pipeline.

Surrozen Gains Momentum as FDA Submission Opens Path for Lead Therapy

Benzinga · 24 Sept 2026positive

Surrozen's stock price surged after the company submitted an Investigational New Drug application to the FDA for SZN-8141, a candidate to treat diabetic macular edema. The submission marks a step forward in advancing the company's lead therapy toward clinical development.

Why it matters — The FDA submission moves Surrozen's lead candidate, SZN-8141, closer to potential clinical trials, a key development milestone for the company.

Surrozen, Inc. (SRZN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha · 16 Sept 2026neutral

Surrozen, Inc. presented at the Morgan Stanley 24th Annual Global Healthcare Conference, and a transcript of the presentation was published by Seeking Alpha. The presentation covers the company's remarks at the conference.

Why it matters — SRZN watchers would care because the transcript provides insight into the company's own messaging and positioning as shared with investors at a major industry conference.

Surrozen Announces Submission of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema

GlobeNewsWire · 8 Sept 2026positive

Surrozen announced it has submitted an Investigational New Drug (IND) application to the U.S. FDA seeking to evaluate SZN-8141, a bifunctional Wnt agonist and VEGF antagonist antibody, for the treatment of diabetic macular edema (DME).

Why it matters — The IND submission is an early regulatory milestone that advances SZN-8141, a novel candidate in Surrozen's ophthalmic pipeline, toward potential clinical testing for DME.

Surrozen to Present at Upcoming Healthcare Investor Conferences

GlobeNewsWire · 2 Sept 2026neutral

Surrozen, Inc. announced that Company management will present at two upcoming healthcare investor conferences. The presentations relate to the company's work developing targeted therapeutics that harness Wnt signaling to address underlying drivers of sight-threatening ophthalmic conditions.

Why it matters — SRZN watchers would care because these conference presentations give management a platform to showcase Surrozen's ophthalmic therapeutics program to the investment community.

FAQ

Frequently asked questions about SRZN stock

What is the SRZN stock price forecast for 2026-2027?

The 6 Wall Street analysts covering Surrozen, Inc. have a median 12-month price target of $52, with estimates ranging from $40 to $54. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SRZN stock a buy right now?

Of the 6 analysts covering Surrozen, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Surrozen, Inc. 77 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SRZN?

As at 8 Oct 2026, Surrozen, Inc. ranks 77 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (94 of 100).

Will SRZN stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts implies +85.9% from the last close, and Ticker Nerd's factor model ranks Surrozen, Inc. 77 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SRZN stock forecast for 2030?

No analyst covering Surrozen, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SRZN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $40 to $54 over the next 12 months.

How has SRZN stock performed over the past year?

Surrozen, Inc. returned +99.2% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Surrozen, Inc. do?

Surrozen, Inc. is a biotechnology company focused on developing antibody-based therapeutics that selectively modulate the Wnt pathway to support tissue repair and regeneration.

What is the latest news on SRZN?

The most recent item we track (GlobeNewsWire, 2 Oct 2026): "Surrozen Announces FDA Clearance of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema". Surrozen announced that its Investigational New Drug application for SZN-8141, a candidate for diabetic macular edema, has become effective, allowing the program to move into clinical development. The first patient in the DUET study is expected to be dosed in the fourth quarter of 2026, and this milestone triggers the second closing of a March 2025 private placement expected to provide approximately $95.1 million in gross proceeds.

Company

About Surrozen, Inc.

Surrozen, Inc. is a biotechnology company focused on developing antibody-based therapeutics that selectively modulate the Wnt pathway to support tissue repair and regeneration. The company’s current programs are centered on ophthalmology, with candidates aimed at retinal diseases, diabetic macular edema, wet age-related macular degeneration, uveitic macular edema, Fuchs’ endothelial corneal dystrophy, and geographic atrophy. Surrozen also works on tissue-specific biologics designed to engage the body’s natural repair mechanisms in other disease areas, including the intestine, liver, lung, kidney, skin, pancreas, and central nervous system. Based in South San Francisco, California, Surrozen’s role in the market is that of a clinical-stage drug developer pursuing precision biologics for serious conditions with high unmet medical need.

CEO Mr. Craig C. Parker M.B.A. · 44 employees · United States · https://www.surrozen.com